检索结果-南通市图书馆

chinese Experts Consensus on Pre-examination and Triage in Dermatology Clinics during the COVID-19 Outbreak

在线全文

学校读者我要写书评

暂无评论

International Journal of Dermatology and Venereology 2020年第2期3卷 65-67页

作者： Ma Lin Wang Gang Mu Qi-Ri Ran Yu-Ping Liu Quan-Zhong Xiao Sheng-Xiang Zhang Xue-Jun Zhang Jian-Zhong Zhang Fu-Ren He Li Chen Ai-Jun Chen Xiang Zheng Jie Yang Rong-Ya Yao Zhi-Rong Tu Ping Li Yu-Zhen Gao Xing-Hua Xu Jin-Hua Gu Heng Cheng Bo Lai Wei Lu Qian-Jin chinese Society of Dermatology Department of Dermatology Beijing Children’s HospitalCapital Medical UniversityBeijing 100045China Department of Dermatology Xijing HospitalThe Fourth MilitaryMedical UniversityXi’anShaanxi 710032China Department of Dermatology InnerMongolia Autonomous Region People’s HospitalHohhotInner Mongolia 010017China Department of Dermatovenereology West China HospitalSichuan UniversityChengduSichuan 610000China Department of Dermatology Tianjin Medical UniversityGeneral HospitalTianjin 300052China Department of Dermatology and Venereology TheSecond Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShaanxi 710004China Department of Dermatology Institute of DermatologyAnhui Medical UniversityHefeiAnhui 230032China Department of Dermatology Peking University People’sHospitalBeijing 100044China Skin Disease Hospital Affiliated to Shandong Firstmedical University JinanShandong 250022China Department of Dermatology FirstAffiliated Hospital of Kunming Medical UniversityKunmingYunnan 650032China Department of Dermatology The First Affiliated Hospital of Chongqing MedicalUniversityChongqing 400016China Department of Dermatology Xiangya HospitalCentral South UniversityChangshaHunan 410008China Department of Dermatology Ruijin HospitalShanghai Jiao Tong University School of MedicineShanghai 200025China Department of Dermatology Seventh Medical Center of PLA General HospitalBeijing 100191China Department of Dermatology Xinhua HospitalShanghai Jiao TongUniversity School of MedicineShanghai 200092China Department of Dermatology Peking University First HospitalBeijing 100034China Department of Dermatology TheSecond Affiliated Hospital of Harbin Medical UniversityHarbinHeilongjiang 150001China Department of Dermatology The First Hospital of China Medical UniversityShenyangLiaoning 110001China Department of Dermatology Huashan HospitalFudanUniversityShanghai 200040China Hospital for Skin Diseases(Institute ofDermatology) Chinese Academy of Medical Sciences and Peking Union Medical

The SARS-CoV-2 infection has brought a great challenge in prevention and control of the national epidemic of coronavirus disease 2019(COVID-19)in *** the COVID-19 epidemic,properly carrying out pre-examination and triage for patients with skin lesions and fever has become a practical problem encountered in hospitals for skin diseases and dermatology clinics in general *** of the carriers of the SARS-CoV-2 and patients with COVID-19 in the early stage may not present with any symptoms of COVID-19,while certain other skin diseases can also cause ***,to properly deal with the patients presenting at dermatology clinics,the chinese Society of Dermatology organized experts to formulate principles and procedures for the pre-examination and triage of patients at dermatology clinics during the COVID-19 epidemic.

关键词： SARS-CoV-2 COVID-19 fever skin disease pre-examination triage

针刺补肾祛瘀法治疗中重度骨转移癌痛的临床研究

在线全文

学校读者我要写书评

暂无评论

世界中西医结合杂志 2018年第1期13卷 116-120页

作者：芦殿荣何生奇冯利芦殿香袁晓玢王芳高音中国中医科学院望京医院肿瘤科北京100102 国家癌症中心中国医学科学院北京协和医学院肿瘤医院中医科北京100102 青海大学医学院高原医学研究中心青海西宁810001

目的评价针刺补肾祛瘀法治疗骨转移疼痛的临床疗效。方法采用前瞻性的随机对照方法,将60例患者随机分为针刺组(3.例)和西药组(3.例),针刺组予针刺加奥施康定(盐酸羟考酮控释片)止痛,西药组予奥施康定止痛治疗,疗程7 d,观察疼痛数字评分(... 详细信息

目的评价针刺补肾祛瘀法治疗骨转移疼痛的临床疗效。方法采用前瞻性的随机对照方法,将60例患者随机分为针刺组(3.例)和西药组(3.例),针刺组予针刺加奥施康定(盐酸羟考酮控释片)止痛,西药组予奥施康定止痛治疗,疗程7 d,观察疼痛数字评分(NRS)、体力状况评分(卡氏评分,KPS)、奥施康定使用量、呕吐、便秘次数等指标的变化情况。结果与本组治疗前比较,两组病例治疗后NRS评分降低、KPS升高,差异有统计学意义。与西药组比较,针刺组治疗后NRS评分明显降低,差异有统计学意义,而治疗后两组KPS评分比较差异无统计学意义。针刺组治疗前后爆发痛次数、呕吐次数和便秘次数比较差异有统计学意义,而西药组治疗前后爆发痛次数、呕吐次数和便秘次数比较差异无统计学意义;两组病例治疗后爆发痛次数比较差异有统计学意义,而呕吐次数和便秘次数比较差异无统计学意义。针刺组治疗前后奥施康定剂量比较差异有统计学意义(P0.05);两组病例治疗后奥施康定剂量比较差异有统计学意义(P<0.05)。两组病例资料后疼痛缓解率比较差异有统计学意义(χ2=6.787,P=0.009)。结论针刺补肾化瘀法联合奥施康定更能有效缓解骨转移疼痛,而且针刺疗法可有效缓解奥施康定呕吐、便秘等副作用,有效改善了患者的生活质量。

关键词：针刺补肾化瘀骨转移癌疼痛

观察消肿止痛颗粒合玻璃酸钠对瘀血闭阻型膝骨关节炎疗效

在线全文

学校读者我要写书评

暂无评论

实用中西医结合临床 2018年第3期18卷 1-3,6页

作者：王荟榛李肖亮程振东兰如华孟建戴刚兰州大学基础医学院甘肃兰州730000 甘肃中医药大学兰州730000 甘肃省中医院兰州730050

目的:观察消肿止痛颗粒联合玻璃酸钠治疗瘀血闭阻型膝骨关节炎的临床疗效。方法:将符合纳入标准的76例膝骨关节炎患者随机分为对照组3.例和治疗组3.例。对照组予玻璃酸钠膝关节腔内注射治疗;治疗组予消肿止痛颗粒口服同时配合玻璃酸钠... 详细信息

目的:观察消肿止痛颗粒联合玻璃酸钠治疗瘀血闭阻型膝骨关节炎的临床疗效。方法:将符合纳入标准的76例膝骨关节炎患者随机分为对照组3.例和治疗组3.例。对照组予玻璃酸钠膝关节腔内注射治疗;治疗组予消肿止痛颗粒口服同时配合玻璃酸钠膝关节腔内注射。分别于治疗前和治疗4周后使用疼痛视觉模拟评分(VAS)以及西安大略和麦克马斯特大学骨关节炎指数评分(WOMAC)对患者的治疗效果进行评估,并在治疗4周后参照《中药新药临床研究指导原则》(2002修订版)中治疗骨关节炎疾病疗效评定标准来评定两组患者的临床疗效。结果:治疗前对照组VAS评分平均为(46.42±13.59)分,治疗组为(44.16±11.74)分,两组间比较差异无统计学意义(P>0.05);治疗后两组VAS平均评分均较治疗前明显降低,差异均有统计学意义(P0.05);治疗后两组患者平均WOMAC评分均较治疗前明显降低,差异均有统计学意义(P3.,治疗组总有效率为94.7%,治疗组疗效明显优于对照组,差异有统计学意义(P<0.05)。结论:口服消肿止痛颗粒联合玻璃酸钠关节腔内注射治疗瘀血闭阻型膝骨关节炎对缓解关节疼痛和僵硬程度、改善活动功能有明确的疗效。

关键词：膝骨关节炎消肿止痛颗粒玻璃酸钠

秋龙筋中药制剂对链脲佐菌素诱导糖尿病大鼠的降糖作用及机制研究

在线全文

学校读者我要写书评

暂无评论

重庆医学 2018年第24期47卷 3138-3141页

作者：林文东杨维群施水液张美佳程晶洪建兵泉州医学高等专科学校基础医学部福建泉州362000 福建省晋江市中西医结合医院内科 362200 福建省泉星生物有限公司福建南安362300

目的探讨秋龙筋中药制剂对链脲佐菌素(STZ)诱导糖尿病大鼠的降糖作用及作用机制,为进一步深入开发提供依据。方法将24只大鼠分为正常组、模型组、阳性药组及实验组,模型组、阳性药组及实验组使用STZ诱导造模。正常组及模型组给予生理盐... 详细信息

目的探讨秋龙筋中药制剂对链脲佐菌素(STZ)诱导糖尿病大鼠的降糖作用及作用机制,为进一步深入开发提供依据。方法将24只大鼠分为正常组、模型组、阳性药组及实验组,模型组、阳性药组及实验组使用STZ诱导造模。正常组及模型组给予生理盐水,阳性药组给予盐酸二甲双胍,实验组给予秋龙筋中药制剂干预。给药结束后检测血清学指标;采集肝脏组织,检测肝糖原水平。结果实验组大鼠血中低密度脂蛋白胆固醇(LDL-C)、血清总胆固醇(TC)、三酰甘油(TG)、空腹血糖(FBG)、丙二醛(MDA)、游离脂肪酸(FFA)、糖化血红蛋白(GHb)、一氧化氮(NO)、肿瘤坏死因子-α(TNF-α)水平明显低于模型组,高密度脂蛋白胆固醇(HDL-C)、超氧化物歧化酶(SOD)、谷胱甘肽(GSH)、肝糖原水平明显高于模型组(P<0.05)。结论采用秋龙筋中药制剂对STZ诱导糖尿病大鼠干预后,可有效降低其体内血糖水平,提高胰腺β细胞功能。

关键词：链脲菌素糖尿病实验性秋龙筋中药制剂降糖作用机制

Guidelines for the diagnosis and treatment of pancreatic cancer in China (2021)

在线全文

学校读者我要写书评

暂无评论

Journal of Pancreatology 2021年第2期4卷 49-66页

作者： Yinmo Yang Xueli Bai Dapeng Bian Shouwang Cai Rufu Chen Feng Cao Menghua Dai Chihua Fang Deliang Fu Chunlin Ge Xiaochao Guo Chunyi Hao Jihui Hao Heguang Huang Zhixiang Jian Gang Jin Fei Li Haimin Li Shengping Li Weiqin Li Yixiong Li Hongzhen Li Tingbo Liang Xubao Liu Wenhui Lou Yi Miao Yiping Mou Chenghong Peng Renyi Qin Chenghao Shao Bei Sun Guang Tan Xiaodong Tian Huaizhi Wang Lei Wang Wei Wang Weilin Wang Junmin Wei Heshui Wu Wenming Wu Zheng Wu Jingyong Xu Changqing Yan Xiaoyu Yin Xianjun Yu Chunhui Yuan Taiping Zhang Jixin Zhang Jun Zhou Yupei Zhao on behalf of the chinese Pancreatic Surgery Association Department of General Surgery Peking University First HospitalBeijing Department of Hepatobiliary and Pancreatic Surgery the First Affiliated Hospital of Medical CollegeZhejiang UniversityHangzhouZhejiang Province Departments of Endoscopy Peking University First HospitalBeijing Institute of Hepatobiliary Surgery of PLA Chinese PLA General HospitalBeijing Department of Pancreatobiliary Surgery Sun Yat-sen Memorial HospitalSun Yat-sen UniversityGuangzhouGuangdong Province Department of General Surgery Xuanwu HospitalCapital Medical UniversityBeijing Department of General Surgery Peking Union Medical College HospitalChinese Academy of Medical Science&Peking Union Medical CollegeBeijing Department of Hepatobiliary Surgery Zhujiang HospitalSouthern Medical UniversityGuangzhouGuangdong Province Department of Pancreatic Surgery Huashan Hospital Fudan UniversityShanghai Department of General Surgery The First Affiliated Hospital of China Medical UniversityShenyangLiaoning Province Department of Imaging Peking University First HospitalBeijing Department of Hepato-Pancreato-Biliary Surgery Peking University Cancer Hospital&InstituteBeijing Department of Pancreatic Cancer Tianjin Medical University Cancer Institute and HospitalTianjin Department of General Surgery Fujian Medical University Union HospitalFuzhouFujian Province Department of General Surgery Guangdong Provincial People’s HospitalGuangzhouGuangdong Province Department of Hepatobiliary Pancreatic Surgery Changhai Hospital Affiliated to Navy Medical UniversityShanghai Department of Hepatobiliary Surgery Xijing HospitalFourth Military Medical UniversityXi’anShaanxi Province Department of Pancreatobiliary Surgery Sun Yat-sen University Cancer CenterGuangzhouGuangdong Province Department of General Surgery Jinling HospitalMedical School of Nanjing UniversityNanjingJiangsu Province Department of General Surgery Xiangya HospitalCentral South UniversityChangshaHunan Province Department of Radiation Oncology Peking University First H

The incidence of pancreatic cancer has been rising worldwide,and its clinical diagnosis and treatment remain a great *** present the update and improvements in the clinical diagnosis and treatment of pancreatic cancer in recent years,chinese Pancreatic Association,the chinese Society of Surgery,chinese {3. Association revised the Guidelines for the Diagnosis and Treatment of Pancreatic Cancer in China(2014)after reviewing evidence-based and problem-oriented literature published during 2015-2021,mainly focusing on highlight issues regarding diagnosis and surgical treatment of pancreatic cancer,conversion strategies for locally advanced pancreatic cancer,treatment of pancreatic cancer with oligo metastasis,adjuvant and neoadjuvant therapy,standardized processing of surgical specimens and evaluation of surgical margin status,systemic treatment for unresectable pancreatic cancer,genetic testing,as well as postoperative follow up of patients with pancreatic *** recommendation items were finally proposed based on the above issues,and the quality of evidence and strength of recommendations were graded using the Grades of Recommendation,Assessment,Development,and Evaluation *** guideline aims to standardize the clinical diagnosis and therapy,especially surgical treatment of pancreatic cancer in China,and further improve the prognosis of patients with pancreatic cancer.

关键词： Diagnosis Guideline Multidisciplinary team Pancreatic cancer Treatment

在线全文

学校读者我要写书评

暂无评论

集中隔离医学观察场所感染防控专家共识

中国感染控制杂志 2022年第6期21卷 511-523页

作者：李春辉蔡虻陈萍陈青陈昆常卫陈修文邓子德邓志红付强付元瑜高晓东贺繁荣贺雄胡必杰胡世雄黄丽菊黄勋江育玲李卫光梁宁刘思娣刘园刘运喜柳恒卓陆群马乐龙马文晖马志鑫茅一萍欧阳娜乔甫任南孙守红田芳芳童德军王云吴红梅颜小利杨帆杨红晖姚希曾翠曾赛男张兵张浩军张晓霞张新蕾张永栋周鹏程宗志勇李六亿吴安华中华预防医学会医院感染控制分会中国医院协会医院感染管理专业委员会中国感染控制杂志编辑委员会中南大学湘雅医院全国医院感染监控管理培训基地国家老年疾病临床医学研究中心(湘雅医院) 湖南长沙410008 北京医院北京100730 四川省成都市公共卫生临床医疗中心四川成都610000 湖南中医药大学第一附属医院湖南长沙410021 湖南医药学院第一附属医院湖南怀化418000 江西省儿童医院江西南昌330006 中山大学附属第三医院广东广州510630 湖南省疾病预防控制中心湖南长沙410028 国家卫生健康委卫生发展研究中心北京100044 怀化市第一人民医院湖南怀化418000 复旦大学附属中山医院上海200032 北京市疾病预防控制中心北京100013 三亚市疾病预防控制中心海南三亚572000 湖南省人民医院湖南长沙410005 山东第一医科大学附属省立医院山东济南250021 河南省人民医院河南郑州450003 邵阳学院附属第一医院湖南邵阳422001 中国人民解放军总医院第一医学中心北京100039 中南大学湘雅二医院湖南长沙410011 浙江大学医学院附属第二医院浙江杭州310009 湖南省儿童医院湖南长沙410007 首都医科大学宣武医院北京100053 安徽省卫生健康委员会综合监督所安徽合肥230002 徐州医科大学附属医院江苏徐州221006 四川大学华西医院四川成都610041 国家卫生健康委卫生健康监督中心北京100007 湖南省中医药研究院附属医院湖南长沙410006 安徽省第二人民医院安徽合肥230012 温州市人民医院浙江温州325000 复旦大学附属华山医院上海200040 长沙市中心医院湖南长沙410018 北京大学第一医院北京100034 中南大学湘雅三医院湖南长沙410013 江苏省卫生监督所江苏南京210009 甘肃省第二人民医院甘肃兰州730000 长治医学院附属和平医院山西长治046000 北京市红十字会急诊抢救中心北京100192 青海大学附属医院青海西宁810001 不详

为科学指导新型冠状病毒肺炎(以下简称新冠肺炎,COVID-19)疫情期间集中隔离医学观察场所内感染防控工作,在早期有效识别感染者的同时,有效避免集中隔离医学观察场所内的交叉感染,中华预防医学会医院感染控制分会、中国医院协会医院感染... 详细信息

为科学指导新型冠状病毒肺炎(以下简称新冠肺炎,COVID-19)疫情期间集中隔离医学观察场所内感染防控工作,在早期有效识别感染者的同时,有效避免集中隔离医学观察场所内的交叉感染,中华预防医学会医院感染控制分会、中国医院协会医院感染管理专业委员会、中国感染控制杂志编辑部组织有关专家共同制定本共识。本共识适用于确诊病例、疑似病例、无症状感染者的密切接触者、密切接触者的密切接触者,以及入境人员或其他根据防控工作需要“应隔尽隔”人员开展集中隔离医学观察时所设置的集中隔离医学观察场所,指导其工作人员正确做好个人防护及防止感染传播工作,避免发生场所内感染及传播。本共识借鉴医疗机构内新型冠状病毒感染防控的基本原则、文件规范,结合集中隔离医学观察场所的特点与实际工作情况,对不同区域工作人员、工作环节开展新型冠状病毒传播的风险评估,并据此对集中隔离医学观察场所的感染防控组织架构、选址布局、人员防护、人员闭环管理、清洁消毒、环境核酸监测、人员健康监测、职业暴露处理及交叉感染判定原则等感控相关工作给予指导。

关键词：新型冠状病毒新型冠状病毒肺炎集中隔离观察感染防控传播

维普期刊数据库博看期刊

Effect of Kuanxiong Aerosol(宽胸气雾剂)on Patients with Angina Pectoris:A Non-inferiority Multi-center Randomized Controlled Trial

在线全文

学校读者我要写书评

暂无评论

chinese Journal of Integrative medicine 2018年第5期24卷 336-342页

作者： YANG Qiao-ning1 BAI Rui-na1 DONG Guo-ju1 GE Chang-jiang2 ZHOU Jing-min3.HUANG Li4 HE Yan 5 WANG Jun6 REN Ai-hua7 HUANG Zhan-quan8 ZHU Guang-li9 LU Shu10 XlONG Shang-quan11 XlAN Shao-xiang12 ZHU Zhi-jun13.SIll Da-zhuo1 LU Shu-zheng2 LI Li-zhi1 CHEN Ke-ji1 Cardiovascular Diseases Center Xiyuan Hospital China Academy of Chinese Medical Sciences Department of Cardiology Beijing Anzhen Hospital Beijing Institute of Respiratory Medicine Capital Medical University Department of Cardiology Zhongshan Hospital Fudan University Department of Cardiology China-Japan Friendship Hospital Department of Cardiology Longhua Hospital Shanghai University of Traditional Chinese Medicine Department of Cardiology Zhejiang Hospital of Integrated Traditional Chinese and Western Medicine Department of Cardiology Zhejiang Hospital Department of Cardiology The First Affiliated Hospital of Zhejiang Chinese Medical University Department of Cardiology Guangxing Hospital Affiliated to Zhejiang Chinese Medical University Department of Cardiology Wuxi Traditional Chinese Medicine Hospital Nanjing University of Traditional Chinese Medicine Department of Cardiology People's Hospital Affiliated Fujian University of Traditional Chinese Medicine Department of Cardiology The First Affiliated Hospital of Guangzhou University of Chinese Medicine Department of Cardiology The 117th Hospital of People's Liberation Army of China

Objective： To evaluate the effect and safety of Kuanxiong Aerosol （宽胸气雾剂, KA） on patients with angina pectoris. Methods： Block randomization was performed to randomly allocate 750 patients into KA （3.6 cases） and control groups （3.4 cases）. During an angina attack, the KA group received 3.consecutive sublingual sprays of KA （0.6 mL per spray）. The control group received 1 sublingual nitroglycerin tablet （NT, 0.5 rag/tablet）. Log-rank tests and Kaplan-Meier estimations were used to estimate the angina remission rates at 6 time-points after treatment （1,2, 3. 4, 5, and 〉5 min）. Logistic regression analysis was performed to observe the factors influencing the rate of effective angina remission, and the remission rates and incidences of adverse reactions were compared for different Canadian Cardiovascular Society （CCS） classes of angina. Results： The 5-min remission rates in the KA and control groups were not significantly different （94.41% vs. 90.64%, P〉0.05）. The angina CCS class significantly influenced the rate of remission （95% confidence interval = 0.483.0.740, P〈0.01）. In the CCS subgroup analysis, the 3. and 5-min remission rates for KA and NT were similar in the CCS I and IV subgroups （P〉0.05）, while they were significantly better for KA in the CCS Ⅱ and Ⅲ subgroups （P〈0.05 or P〈0.01）. Furthermore, the inciden0ce of adverse reactions was significantly lower in the KA group than in the control group for the CCS Ⅱ and Ⅲ subgroups （9.29% vs. 26.22%, 10.13. vs. 20.88%, P〈0.05 or P〈0.01）. Conclusions： KA is not inferior to NT in the remission of angina. Furthermore, in CCS Ⅱ and Ⅲ patients, KA is superior to NT, with a lower incidence of adverse reactions. （Registration No. ChiCTR- IPR-15007204）

关键词： Kuanxiong Aerosol angina pectoris Canadian Cardiovascular Society classification of angina randomized controlled trial chinese medicine

上颌窦底提升中骨增量材料的专家共识:自体骨

在线全文

学校读者我要写书评

暂无评论

中国口腔种植学杂志 2022年第5期27卷 269-273页

作者：中华口腔医学会口腔种植专业委员会吴轶群宿玉成周文洁王凤不详上海交通大学医学院附属第九人民医院口腔第二门诊部 201999 中国医学科学院北京协和医院口腔种植中心 100032 上海交通大学医学院附属第九人民医院

自体骨来源于患者自身,具有骨生成、骨诱导和骨引导特性,且无免疫排斥和疾病传播的风险。因此,自体骨长久以来被视作骨增量材料的“金标准”。本文依据循证的原则,就骨增量材料的生物学特性、自体骨的获取、自体骨植入上颌窦底后的成骨... 详细信息

自体骨来源于患者自身,具有骨生成、骨诱导和骨引导特性,且无免疫排斥和疾病传播的风险。因此,自体骨长久以来被视作骨增量材料的“金标准”。本文依据循证的原则,就骨增量材料的生物学特性、自体骨的获取、自体骨植入上颌窦底后的成骨过程和临床疗效以及自体骨的局限性进行总结,并依据国内部分专家的临床经验提出共识观点。

关键词：上颌窦底提升骨增量材料自体骨专家共识

上颌窦底提升中骨增量材料的专家共识:生物活性制剂、细胞疗法与不植入骨增量材料的上颌窦底提升

在线全文

学校读者我要写书评

暂无评论

中国口腔种植学杂志 2022年第6期27卷 329-333页

作者：中华口腔医学会口腔种植专业委员会吴轶群宿玉成王宁涛王凤不详上海交通大学医学院附属第九人民医院口腔第二门诊部 201999 中国医学科学院北京协和医院口腔种植中心 100032 上海交通大学医学院附属第九人民医院

上颌窦底提升是解决上颌后牙区垂直向骨量不足的可靠方法。目前应用于上颌窦底骨增量的材料较多,关于材料的选择尚无统一共识。本文基于现有临床文献证据,针对生物活性制剂、细胞疗法以及不植入骨增量材料的上颌窦底提升进行总结及阐述... 详细信息

上颌窦底提升是解决上颌后牙区垂直向骨量不足的可靠方法。目前应用于上颌窦底骨增量的材料较多,关于材料的选择尚无统一共识。本文基于现有临床文献证据,针对生物活性制剂、细胞疗法以及不植入骨增量材料的上颌窦底提升进行总结及阐述,以期为临床上颌窦底提升中骨增量材料的选择提供参考。

关键词：上颌窦底提升骨增量材料骨形态发生蛋白自体血小板浓缩制品干细胞不植入骨增量材料的上颌窦底提升专家共识